FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line trea
Roche (SIX: RO, ROG; OTCQX: RHHBY) has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib).
Click on this link for more information.
